Form 4: Neogenomics Director Lynn A. Tetrault Reports Stock Transactions
SEC Form 4 Filing
Director Lynn A. Tetrault reported the release of restricted stock units and subsequent ownership of common stock in Neogenomics Inc.
Summary
- On August 10, 2024, Lynn A. Tetrault, a director of Neogenomics Inc., reported the release of 11,336 restricted stock units, which converted into common stock.
- Following this transaction, Tetrault directly owns 61,398 shares of Neogenomics common stock.
- Tetrault also holds various stock options with different exercise prices and expiration dates, as well as additional restricted stock units.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, which is common in publicly traded companies. It provides transparency to investors regarding the actions of company leadership.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading.
- Companies like Exact Sciences (EXAS) and Guardant Health (GH) also have similar insider transaction filings, reflecting the common regulatory requirements in the diagnostics industry.
Stakeholder Impact
- The filing provides transparency to shareholders regarding insider transactions.
- It can influence investor sentiment depending on the nature and volume of the transactions.
Key Dates
| Date | Description |
|---|---|
| 06/06/2020 | Date of grant for stock options exercisable until 06/06/2026 at $22.52 |
| 05/28/2021 | Date of grant for stock options exercisable until 05/28/2027 at $28.54 |
| 06/02/2022 | Date of grant for stock options exercisable until 06/02/2028 at $40.9 |
| 10/11/2022 | Date of grant for stock options exercisable until 10/11/2028 at $41.76 |
| 06/10/2023 | Date of grant for stock options exercisable until 06/10/2029 at $8.1 |
| 08/10/2024 | Release of restricted stock units and conversion to common stock; Date of grant for stock options exercisable until 08/10/2033 at $14.82 |
| 06/01/2025 | Vesting date for restricted stock units exercisable until 06/01/2034 at $13.71 |
| 08/13/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.